Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Clinical Trial of Patients With Solid Tumours Receiving Granocyte 34 (Granulocyte Colony Stimulating Factor (G-CSF)) as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Taxotere (Docetaxel) Based Regimen

NCT01107756 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01107756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01107756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Clinical Trial of Patients With Solid Tumours Receiving Granocyte 34 (Granulocyte Colony Stimulating Factor (G-CSF)) as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Taxotere (Docetaxel) Based Regimen
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2010
Completion date
July 31, 2012
Enrollment
403 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms (no otherwise specified)